Clinical trials: SARS
COVID-19
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine
This trial is observer-blind, comparative, randomized, placebo-controlled phase 2 study. The population is healthy subjects aged 18 and above
- Trial name
- NCT05313035
- Testing
- SARS-CoV-2 protein subunit recombinant vaccine
- Where
- 3 sites in Indonesia
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Covid19
PCR Cycle Threshold Values and COVID-19 Outcomes
This is a retrospective observational study. The study will use high quality, reliable data that has already been collected for the ISARIC 4C COVID-19 study in order to analyse the relation between predictor variables (laboratory…
- Trial name
- NCT04651413
- Testing
- PCR Value
- Where
- United Kingdom
- Volunteers
- 934 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Coronavirus Infection
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device in healthy adult…
- Trial name
- NCT04336410
- Testing
- INO-4800, CELLECTRA® 2000
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
SARS-COV2 Infection, Covid19
Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum
For an antiviral agent to act as an effective biological barrier on nasal mucosal surface, the formulation preferably has to be maintained on the site of action for several hours, and the nasal spray dispenser can be utilized for…
- Trial name
- NCT04916574
- Testing
- Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
- Where
- Estonia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Icosagen Cell Factory
Coronavirus
Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19
The purpose of this study is to test over time immunity to SARS-CoV-2, a recently identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as COVID-19.
- Trial name
- NCT04373148
- Testing
- There is no intervention
- Where
- 2 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Stanford University
Covid-19, SARS-CoV-2
Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR
The performance of 3 different sampling methods (2 nasopharyngeal swabs, 1 oropharyngeal swab) for the detection of SARS-CoV-2 with real-time reverse transcriptase polymerase chain reaction will be compared.
- Conditions
- Covid-19, SARS-CoV-2, Diagnosis, Polymerase Chain Reaction
- Trial name
- NCT04361448
- Testing
- samling of oropharynx and nasopharynx
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jessa Hospital
Covid19
Face Masks to Reduce SARS-CoV-2 Infections (COVID-19) in Bangladesh
The primary goal of the village-level intervention is to assess whether mask-wearing reduces community-level asymptomatic and symptomatic SARS-CoV-2 infections, assessed via PCR testing.
- Trial name
- NCT05197725
- Testing
- Face mask, Face mask awareness, Face mask promotion through community values or individual information
- Where
- Bangladesh
- Volunteers
- healthy volunteers welcome
- Sponsor
- Yale University
Pneumococcal Infection
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease…
- Trial name
- NCT05158140
- Testing
- V110, V114, mRNA-1273
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, SARS-CoV-2
NOWDx Test for the Detection of Antibodies to COVID-19
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device.
- Conditions
- COVID-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04690413
- Testing
- NOWDx COVID-19 Test
- Where
- 3 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- NOWDiagnostics, Inc.
COVID-19, Burnout
Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic
Healthcare systems around the world have faced tremendous stress because of the COVID-19 pandemic. Healthcare workers (HCWs) (ie.
- Conditions
- COVID-19, Burnout, Burnout, Professional, Work-related Illness
- Trial name
- NCT05394051
- Testing
- Positive Affect Regulation sKills (PARK)
- Where
- United States
- Volunteers
- 555 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Covid19, SARS-CoV Infection
Effectiveness of a Novel Respirator With Chitosan Nanoparticles
The use of nanomaterials in semi-facial respirators could decrease the permeability of particles and promote a biocidal effect compared to conventional respirators (N95) and, therefore, to enhance the filtering power, aiming to…
- Conditions
- Covid19, SARS-CoV Infection, Worker-Patient Transmission, Healthcare
- Trial name
- NCT04490200
- Testing
- VESTA respirator, Conventional N95 respirator
- Where
- Brazil
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Brasilia
COVID-19
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04758273
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Healthy
Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults
The purpose of this study is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants.
- Trial name
- NCT04590430
- Testing
- HFB30132A
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HiFiBiO Therapeutics
SARS CoV 2 Infection
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.
- Trial name
- NCT06234956
- Testing
- BIMERVAX
- Where
- 7 sites in Spain
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
SARS CoV 2 Infection, COVID-19 Breakthrough
SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia
In this study we aim to characterize SARS CoV-2 strain specific immune response (SARS-CoV-2 Spike IgG) in health care workers and general populations at the Jimma Medical Center and the St.
- Conditions
- SARS CoV 2 Infection, COVID-19 Breakthrough, COVID-19 Recurrent
- Trial name
- CoVICIS (NCT06435403)
- Where
- 2 sites in Ethiopia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Michael Hoelscher
SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory…
- Trial name
- NCT06585241
- Testing
- mRNA-1273 Variant-containing Formulation
- Where
- 6 sites in United States
- Volunteers
- 1,144 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV2 Infection
Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2
This study will analyze the safety and efficacy of the heterologous vaccination with Vaxzevria followed by Comirnaty. As a control individuals will be vaccinated with Comirnaty or Vaxzevria twice.
- Trial name
- HeVacc (NCT04907331)
- Testing
- Vaxzevria, Comirnaty
- Where
- Austria
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
SARS-COV-2
Level of Immunity, Neutralization of the COVID-19 Virus and Reinfections in Residents of 2 Migrant Workers' Residences
A previous seroprevalence survey showed very high seroprevalence levels among residents of the two among the residents of the two migrant workers' hostels surveyed, indicating a high level of circulation of the virus SARS-COV-2…
- Trial name
- NCT04932837
- Testing
- Blood and Saliva collection
- Where
- 2 sites in France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Epicentre
COVID-19
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine
Observer-blind, randomized, active-controlled prospective intervention study
- Trial name
- NCT05433285
- Testing
- COVID-19 Protein Subunit Recombinant Vaccine, Active Comparator
- Where
- 4 sites in Indonesia
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Vaccine
Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"
Randomized, double-blind, placebo controlled, multi-center clinical trials of the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified vaccine against COVID-19, manufactured by FSBSI…
- Trial name
- NCT05715918
- Testing
- Vaccine for intramuscular injection
- Where
- 4 sites in Russia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.